235 related articles for article (PubMed ID: 36378537)
1. mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection.
Ando S; Perkins CM; Sajiki Y; Chastain C; Valanparambil RM; Wieland A; Hudson WH; Hashimoto M; Ramalingam SS; Freeman GJ; Ahmed R; Araki K
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36378537
[TBL] [Abstract][Full Text] [Related]
2. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1
Hudson WH; Gensheimer J; Hashimoto M; Wieland A; Valanparambil RM; Li P; Lin JX; Konieczny BT; Im SJ; Freeman GJ; Leonard WJ; Kissick HT; Ahmed R
Immunity; 2019 Dec; 51(6):1043-1058.e4. PubMed ID: 31810882
[TBL] [Abstract][Full Text] [Related]
3. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
Front Immunol; 2021; 12():648420. PubMed ID: 34589081
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells.
Viramontes KM; Neubert EN; DeRogatis JM; Tinoco R
Front Immunol; 2022; 13():869768. PubMed ID: 35774790
[TBL] [Abstract][Full Text] [Related]
5. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
7. A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells.
Knuschke T; Kollenda S; Wenzek C; Zelinskyy G; Steinbach P; Dittmer U; Buer J; Epple M; Westendorf AM
mBio; 2021 Feb; 12(1):. PubMed ID: 33531395
[TBL] [Abstract][Full Text] [Related]
8. TIM-3 as a marker of exhaustion in CD8
Mohammadizad H; Shahbazi M; Hasanjani Roushan MR; Soltanzadeh-Yamchi M; Mohammadnia-Afrouzi M
Microb Pathog; 2019 Mar; 128():323-328. PubMed ID: 30660734
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade.
Jadhav RR; Im SJ; Hu B; Hashimoto M; Li P; Lin JX; Leonard WJ; Greenleaf WJ; Ahmed R; Goronzy JJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14113-14118. PubMed ID: 31227606
[TBL] [Abstract][Full Text] [Related]
10. miR-149-3p reverses CD8
Zhang M; Gao D; Shi Y; Wang Y; Joshi R; Yu Q; Liu D; Alotaibi F; Zhang Y; Wang H; Li Q; Zhang ZX; Koropatnick J; Min W
Open Biol; 2019 Oct; 9(10):190061. PubMed ID: 31594465
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
12. PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors.
Gill AL; Wang PH; Lee J; Hudson WH; Ando S; Araki K; Hu Y; Wieland A; Im S; Gavora A; Medina CB; Freeman GJ; Hashimoto M; Reiner SL; Ahmed R
Sci Immunol; 2023 Aug; 8(86):eadg0539. PubMed ID: 37624909
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
14. CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy.
Ando S; Araki K
Int Immunol; 2022 Oct; 34(11):571-577. PubMed ID: 35901837
[TBL] [Abstract][Full Text] [Related]
15. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
16. CD8
Tao J; Han D; Gao S; Zhang W; Yu H; Liu P; Fu R; Li L; Shao Z
J Cell Mol Med; 2020 Jan; 24(1):1046-1058. PubMed ID: 31756785
[TBL] [Abstract][Full Text] [Related]
17. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Im SJ; Hashimoto M; Gerner MY; Lee J; Kissick HT; Burger MC; Shan Q; Hale JS; Lee J; Nasti TH; Sharpe AH; Freeman GJ; Germain RN; Nakaya HI; Xue HH; Ahmed R
Nature; 2016 Sep; 537(7620):417-421. PubMed ID: 27501248
[TBL] [Abstract][Full Text] [Related]
18. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions.
Hashimoto M; Kamphorst AO; Im SJ; Kissick HT; Pillai RN; Ramalingam SS; Araki K; Ahmed R
Annu Rev Med; 2018 Jan; 69():301-318. PubMed ID: 29414259
[TBL] [Abstract][Full Text] [Related]
19. Double Positive CD4
Kochanowicz AM; Osuch S; Berak H; Kumorek A; Caraballo Cortés K
Cells; 2023 May; 12(10):. PubMed ID: 37408280
[TBL] [Abstract][Full Text] [Related]
20. Effects of immune checkpoint blockade on antigen-specific CD8
Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]